Inhibrx

Overview

Inhibrx, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutic proteins using its proprietary single-domain antibody (sdAb) and multi-specific antibody platforms. The company is applying its technology to generate treatments for oncology, immunology, and neurodegenerative diseases["@inhibrx"].

Overview

Inhibrx, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutic proteins using its proprietary single-domain antibody (sdAb) and multi-specific antibody platforms. The company is applying its technology to generate treatments for oncology, immunology, and neurodegenerative diseases["@inhibrx"].

Founded in 2010, Inhibrx has built a differentiated platform based on camelid-derived single-domain antibodies (nanobodies), which offer unique properties including small size, high affinity, stability, and the ability to engage multiple targets simultaneously["@sdib"].

Funding

• IPO: 2020 (NASDAQ: INBX)
• Market Cap: ~$200M

Pipeline Overview

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| INBRX-101 | [Alpha-synuclein](/proteins/alpha-synuclein) antibody | Parkinson's Disease | Preclinical | Research |
| INBRX-105 | [Tau](/proteins/tau) antibody | Alzheimer's Disease | Preclinical | Research |
| INBRX-109 | 4-1BB agonist | Oncology | Phase 1 | Active |
| INBRX-106 | PD-L1/4-1BB | Oncology | Phase 1 | Active |
| INBRX-102 | Undisclosed | CNS disorder | Discovery | Research |

Neurodegeneration Programs

INBRX-101 (Alpha-Synuclein)

INBRX-101 is a single-domain antibody targeting alpha-synuclein aggregates for Parkinson's disease and related disorders. The sdAb platform offers advantages in tissue penetration and clearance of aggregated proteins[@inbrx].

Mechanism of Action:

• Binds to alpha-synuclein aggregates
• Promotes clearance via Fc-mediated mechanisms
• Blocks cell-to-cell transmission
• Prevents aggregation seeding

• Small size (~12 kDa)
• High affinity and specificity
• Excellent tissue penetration
• Stable and manufacturable
• Multiple binding modalities

• Preclinical development
• IND-enabling studies planned
• Focus on Parkinson's disease

INBRX-105 (Tau)

INBRX-105 is a tau-targeting single-domain antibody in preclinical development for Alzheimer's disease. The program leverages the same sdAb platform as INBRX-101[@alphasynuclein2024].

Target:

• Pathological tau aggregates
• [Tau](/proteins/tau) oligomers and fibrils
• [Neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)

• [Tau](/proteins/tau) pathology correlates with cognitive decline
• Small size enables brain penetration
• Enhanced clearance mechanisms

INBRX-102

INBRX-102 is an undisclosed CNS program in discovery research:

• Target: Novel neurodegenerative target
• Indication: CNS disorder
• Stage: Discovery
• Approach: sdAb platform

Technology Platforms

Single-Domain Antibody (sdAb) Platform

Inhibrx's proprietary platform enables development of next-generation biologics:

| Feature | Benefit |
|---------|---------|
| Small size | Better tissue penetration |
| High affinity | Potent target engagement |
| Stability | Extended half-life, manufacturing |
| Multi-specificity | Simultaneous targeting |
| Humanization | Reduced immunogenicity |

SDIB Technology

The company's SDIB (Single Domain Inverted Binder) platform enables multi-specificity:

• Multiple sdAbs in single molecule
• Flexible arrangement
• Optimized pharmacokinetics
• Manufacturing efficiency

Oncology Programs

INBRX-109 (4-1BB Agonist)

INBRX-109 is a tetra-valent 4-1BB agonist in Phase 1 clinical trials for solid tumors:

• Target: 4-1BB (CD137)
• Mechanism: Immune checkpoint modulation
• Status: Phase 1 recruiting

INBRX-106 (PD-L1/4-1BB)

INBRX-106 is a bi-specific antibody targeting PD-L1 and 4-1BB:

• Target: PD-L1 + 4-1BB
• Mechanism: Dual immune modulation
• Status: Phase 1 recruiting

Preclinical Data

INBRX-101

Key preclinical findings:

• High affinity for alpha-synuclein aggregates
• Blocks oligomer formation
• Prevents cell-to-cell spread
• Good brain penetration in models
• Favorable safety profile

INBRX-105

Key preclinical findings:

• Binds multiple tau species
• Prevents tau aggregation
• Reduces tau pathology in models
• Central nervous system exposure

Manufacturing

Inhibrx has established internal manufacturing capabilities:

• GMP production facility
• sdAb manufacturing platform
• Scalable processes
• Quality control systems

Partnerships

| Partner | Focus Area | Status |
|---------|------------|--------|
| Bristol Myers Squibb | SDIB technology | Collaboration |
| Academic collaborators | Research | Multiple |
| CRO partners | Clinical development | Active |

Financial Information

• Market cap: ~$200 million (2024)
• Cash position: Sufficient for operations
• R&D budget: Focused on core programs
• Employees: ~150

Key Personnel

• Dr. Mark A. H. L. McGhee - President and CEO
• Dr. John C. W. Petersen - Co-Founder and CSO
• Dr. Raymond J. K. L. Chow - Chief Medical Officer
• Jennifer K. W. Liu - Chief Financial Officer

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Annovis Bio](/companies/annovis-bio)
• [ProMIS Neurosciences](/companies/promis-neurosciences)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References